Clinical TrialJun 29, 2026, 08:37 AM
Alaunos Reports ALN1003 Preclinical Data Showing Lower Liver Weight
AI Summary
Alaunos Therapeutics announced new preclinical statistical analysis for its investigational metabolic candidate, ALN1003. In a 48-day diet-induced obesity mouse study, ALN1003-treated animals exhibited lower liver weight after adjusting for body fat percentage, a finding directionally consistent with previous data on liver markers, histology, HOMA-IR, and adipose endocrine biomarkers. The company emphasized that these are non-GLP preclinical findings and may not translate to human efficacy or safety, urging appropriate caution.
Key Highlights
- ALN1003-treated animals showed lower liver weight after adjustment for body fat percentage in a 48-day DIO mouse study (p=0.000005).
- The finding suggests lower liver weight was not fully explained by measured body fat percentage in the model.
- Results are directionally consistent with previously disclosed lower liver injury enzymes, lower NAFLD Activity Scores (NAS), and lower HOMA-IR.
- Findings also align with favorable adipose endocrine biomarker changes, including numerically lower leptin and significantly higher adiponectin.
- The data is from non-GLP preclinical studies and should be interpreted with caution, as ALN1003 has not been evaluated in human clinical trials.
- An investor presentation with integrated data summaries and analyses is available on the company's website.
Price Impact
More from TCRT